Landscapes / Companies
Pharmacosmos A/S not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 approved
1 in Phase 2
Drugs
3
in active trials · 4 in all
Trials
5 active
6 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Approved | 30 Apr 2027Phase 3 trial completes | |||
| Next date | 30 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Iron Deficiency, Anaemia in Children, Chronic Heart Failure and 1 more | ||||
| Open drug page | |||||
Cyclin-dependent kinase inhibitor |
Approved | 15 Jul 2027Phase 3 trial completes | |||
| How it works | Blocks CDK enzymes that let cells divide | ||||
| Next date | 15 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Extensive-stage Small-cell Lung Cancer, Limited Stage Small Cell Lung Cancer and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | Oct 2027Phase 2 trial completes | |||
| Next date | Oct 2027 · Phase 2 trial completes | ||||
| Also tested for | Beta Thalassemia Major Anemia, Myelodysplastic Syndrome | ||||
| Open drug page | |||||
About
- No active trial
- Iron Isomaltoside
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021